Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Prepaid Assets of $514910.0 for Q1 2026, up 881.25% year-over-year from $52475.0 in Q1 2025, and down 48.61% quarter-over-quarter from $1.0 million in Q4 2025.
Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Prepaid Assets for 7 consecutive years, with $514910.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 881.25% year-over-year to $514910.0; the TTM figure through Mar 2026 stood at $514910.0 (up 881.25% YoY), while the FY2025 annual figure was $1.0 million, up 21.24% from the prior year.
- Prepaid Assets slipped to $514910.0 in Q1 2026 per IKT's latest filing, from $1.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $1.2 million in Q1 2022 and bottomed at $52475.0 in Q1 2025.
- Historically, Prepaid Assets has averaged $627276.5 across 5 years, with a median of $682628.0 in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets surged 944.5% — and 2024, when it slumped 77.52%.
- Inhibikase Therapeutics' Prepaid Assets stood at $1.1 million in 2022, then sank by 33.86% to $739179.0 in 2023, then climbed by 11.81% to $826473.0 in 2024, then climbed by 21.24% to $1.0 million in 2025, then slumped by 48.61% to $514910.0 in 2026.
- Business Quant data shows IKT's Prepaid Assets at $514910.0 in Q1 2026, $1.0 million in Q4 2025, and $210566.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 514,910.00 |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 210,566.00 |
| Jun 30, 2025 | 682,628.00 |
| Mar 31, 2025 | 52,475.00 |
| Dec 31, 2024 | 826,473.00 |
| Sep 30, 2024 | 280,914.00 |
| Jun 30, 2024 | 306,300.00 |
| Mar 31, 2024 | 207,422.00 |
| Dec 31, 2023 | 739,179.00 |
| Sep 30, 2023 | 347,565.00 |
| Jun 30, 2023 | 543,923.00 |
| Mar 31, 2023 | 922,764.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 932,419.00 |
| Jun 30, 2022 | 811,482.00 |
| Mar 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 107,000.00 |
| Sep 30, 2021 | 264,381.00 |